Shares of Devonian Health Group Inc. (CVE:GSD – Get Free Report) traded down 23.5% during mid-day trading on Saturday . The company traded as low as C$0.09 and last traded at C$0.13. 119,000 shares traded hands during mid-day trading, an increase of 588% from the average session volume of 17,288 shares. The stock had previously closed at C$0.17.
Devonian Health Group Price Performance
The business’s 50-day simple moving average is C$0.16 and its 200-day simple moving average is C$0.17. The stock has a market cap of C$19.27 million, a PE ratio of -4.64 and a beta of 0.67. The company has a quick ratio of 7.82, a current ratio of 1.07 and a debt-to-equity ratio of 16.36.
Devonian Health Group Company Profile
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics.
See Also
- Five stocks we like better than Devonian Health Group
- What Is WallStreetBets and What Stocks Are They Targeting?
- 3 Overlooked Value Stocks Set to Surge as Rates Drop
- When to Sell a Stock for Profit or Loss
- Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy
- P/E Ratio Calculation: How to Assess Stocks
- After the Fed’s Rate Cut, PNC Could See a Mortgage Refinance Boom
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
